🇺🇸

US SEC Filing Intelligence

· daily

US Corporate Distress Financial Stress SEC Filings — May 14, 2026

Across 50 8-K filings in the USA Corporate Distress & Bankruptcy stream (May 14, 2026 period), overarching themes include aggressive debt refinancing (25+ issuances/amendments totaling billions, e.g., Lumen $2.4B, IREN $3B, Constellation $2.2B) to extend maturities and repay near-term obligations, signaling proactive deleveraging amid higher rates rather than outright insolvency. Explicit distress peaks with Trinseo's $2B debt-cut RSA via pre-pack Chapter 11, Society Pass's Chapter 11 filing, and FREIT's liquidation plan (60-97% premium), representing 6% of filings but high materiality (10/10). Where period data available, trends mixed: Applied Materials +11% YoY revenue, +0.8pts gross margin to 49.9%, EPS +33% YoY contrasts HyOrc/GridAI dilutive raises; no broad insider selling/buying patterns noted. Capital allocation favors refinancings/repayments over dividends/buybacks (e.g., AEP forward sales, Tyler $1.4B notes + repurchases). Forward catalysts cluster in Q3 2026 (acquisitions, closings). Portfolio-level: moderate distress with refinancings mitigating bankruptcy risks, but REIT/energy small caps vulnerable; relative outperformance in semis/utilities.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — May 14, 2026

Across 24 filings in the USA Executive & Director Changes stream (May 14, 2026), dominant themes include orderly C-suite retirements with named successors in insurance (RenaissanceRe CFO/CPO retire Dec 2026/Jan 2027, Selective CIO retires June 2026), sudden separations without detailed reasons (CSX CTO immediate exit, Ocugen CMO May 8, Xponential COO May 13), and positive board appointments in financials/biotech (AIG independent director June 1, Corbus pharma veteran ahead of ASCO). Capital allocation remains bullish with new $5B CSX share repurchase (atop $989M remaining) and $3B KeyCorp program replacing $1B prior ($280M left), signaling management confidence amid stable dividends. Annual meetings showed strong approvals but pockets of opposition (e.g., CSX director votes 299M against, Fulgent 6M withheld on director). NeoVolta outlier with 262% 9-mo revenue growth to $13.3M despite flat Q3, gross margins +20pp to 46%; no broad YoY/QoQ deterioration but diverse sectors limit portfolio trends. Implications: Succession planning enhances stability (positive for insurers), abrupt exits flag monitoring (COO/CTO roles), buybacks boost returns in transport/banks.

24 high priority 24 total filings
· daily

US Bankruptcy Chapter 11 Insolvency SEC Filings — May 14, 2026

The USA Bankruptcy & Insolvency stream features a single high-materiality (10/10) Chapter 11 filing by Society Pass Incorporated (SOPA), signaling acute financial distress in the travel and media sectors. No period-over-period financial trends are detailed in the filing, but the voluntary petition implies severe liquidity constraints and operational challenges culminating in bankruptcy on May 12, 2026. Key developments include joint administration in the Southern District of Texas, operations continuing as debtors-in-possession, and a default under the Prepetition Insurance Agreement with automatic stay on enforcement. Equity trading on Nasdaq is deemed highly speculative with substantial risks, likely leading to significant shareholder value erosion. Negative sentiment dominates, with no bullish indicators from insider activity, capital allocation, or forward-looking guidance beyond first-day motions. Portfolio-level implications highlight insolvency risks for small-cap travel/media firms amid economic pressures.

1 high priority 1 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 14, 2026

The 24 filings reveal a surge in boardroom stability through annual meetings (Fulgent, CSX, Cushman, DMC Global, Delcath, InfuSystem) with director elections mostly passing despite notable opposition in Fulgent (up to 6M withheld for Groves) and CSX (299M against Zillmer). Executive transitions dominate, with orderly retirements and appointments (Selective CIO to interim, RenaissanceRe CFO/CPO to internal successors Jan 2027, AIG independent dir Jun 1, Standex CFO promo), but abrupt separations (CSX EVP immediate, Ocugen CMO May 8, Xponential COO May 13) raise flags. Capital allocation shines with CSX's $5B buyback atop $989M remaining and KeyCorp's $3B program replacing $1B ($280M left) plus $0.205 dividend; equity plans approved widely (Fulgent 2M+1.5M shares, Cushman 12M+, Delcath +1.8M). NeoVolta outlier with Q3 revenue flat YoY at $2M but 9-mo +262% to $13.3M, margins 46% vs 26% YoY despite wider $3M loss. Portfolio trends: Positive sentiments in 7/24 (e.g., insurance, fitness), mixed/neutral elsewhere; no broad insider selling but appointments signal conviction. Implications: Bullish for capital returns in financials/transport, monitor governance dissent and transitions for execution risks.

24 high priority 24 total filings
· daily

US Merger & Acquisition SEC Filings — May 14, 2026

The 16 filings reveal a surge in SPAC activity with 10 new or progressing blank check companies (IPOs, unit separations, extensions, and de-SPAC advancements), signaling robust M&A appetite amid a tight deadline environment, while 5 major acquisitions completed on May 14, 2026, across pharma (Apellis/Biogen), telecom (CSG/NEC), marine (Off The Hook/Apex), and homebuilding (Tri Pointe/Sumitomo). Period-over-period trends show SPACs like Boost Run (Willow Lane) posting net income growth to $3.4M in 2025 from $0.1M in 2024 driven by trust interest, but cash declines and widening deficits highlight liquidity strains common to 4/16 filings. Completed deals emphasize accretive synergies (Biogen EPS boost 2027, Off The Hook millions in savings), with forward-looking catalysts like CVRs up to $4/share and Phase 3 data H1 2027. Portfolio-level patterns indicate SPAC extensions averting liquidation (e.g., GP-Act III to Nov 2026), but going concern doubts in 3 SPACs and proxy risks in Mountain Lake underscore execution risks. Market implications include heightened M&A momentum in US equities, favoring acquirers like Biogen and Sumitomo for growth, while SPACs offer de-SPAC alpha if targets materialize.

16 high priority 16 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 14, 2026

Across 50 overnight SEC filings, Q1 2026 results dominate with mixed sentiments: 12/25 10-Qs showed revenue growth averaging +45% YoY (e.g., Lifeway +37%, Intelligent Bio +46%, Karman +51%), but 8 reported declines averaging -35% YoY (e.g., New Fortress -52%, Swarmer -82%), highlighting sector divergence in consumer/health vs energy/tech. SPACs (10 filings) exhibit stability via trust interest income (avg +$1.5M/quarter offsetting operating losses), though cash burns and deficits persist. Debt refinancings (Lumen, Encore upsized €325M notes) and offerings signal financial maneuvers amid positive capital access, while biotech advances (Onconetix publications, Editas 90% LDL-C reduction) provide catalysts. No insider trading reported across filings, but capital allocation trends favor dividends/distributions (Blue Owl +7% payout, News Corp $1B buyback program). Portfolio-level: Margin expansions in 5 firms (Lifeway +360bps, Intelligent Bio +170bps), but compressions in others (Springbig gross -16.8%). Implications: Favor health/consumer outperformers pre-market; monitor SPAC extensions/deadlines for M&A catalysts.

33 high priority 17 medium 50 total filings
· daily

Federal Construction & Infrastructure Contracts — May 13, 2026

This digest synthesizes $1,720,040,000 in federal construction and infrastructure contracts over May 13, 2026, with a 0/1 defense-civilian split—all civilian obligations led by Department of Homeland Security. The dominant theme is DHS infrastructure investment via a single $1.72B award to SOUTHWEST VALLEY CONSTRUCTORS CO. Highest-conviction bullish signal (7/10 strength, 8/10 materiality) highlights the company's positioning in large-scale federal construction. No defense signals present, emphasizing civilian sector momentum. Key risk: unknown competition and pricing structures expose potential margin pressures or protest vulnerabilities. Watch DHS budget execution for follow-on opportunities amid construction sector growth.

1 total filings
· daily

DHS Homeland Security Contracts — May 13, 2026

DHS drove the entire $1,720,040,000 obligation in this period via a single contract award to SOUTHWEST VALLEY CONSTRUCTORS CO on May 11, 2026. This represents a 100% civilian split (0/1 defense-related), with DHS as the dominant agency focusing on homeland security construction. The highest-conviction signal is bullish on SOUTHWEST VALLEY CONSTRUCTORS CO, rated 7/10 strength and 8/10 materiality, indicating potential growth in civilian infrastructure. One key risk is the unknown competition signal, which could expose the award to protests. Watch for details on pricing structure and contract vehicle to gauge durability amid DHS budget priorities.

1 total filings
· daily

VA Healthcare & Services Contracts — May 13, 2026

The Department of Veterans Affairs awarded Booz Allen Hamilton Inc. a single $809,754,946 delivery order for IT operations and services transformation, representing 100% civilian exposure with 0/1 defense-related contracts. This fully committed time-and-materials contract under full and open competition provides high funding certainty through 2025-01-22, with $317,898,571 already outlayed and steady annual revenue estimated at $140-145 million. The dominant agency theme is VA healthcare IT services modernization via NAICS 541512 and PSC D318. Highest-conviction bullish signal is Booz Allen's stable multi-year VA revenue stream amid low pricing risk. Key watch item: progress on remaining ~$492 million outlays and any modifications to the 2025-01-22 end date amid uncertain pacing.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — May 13, 2026

HHS awarded $1,574,385,405 in healthcare contracts from May 13, 2026, all civilian with zero defense-related activity, dominated by BARDA/ASPR funding for viral vaccine R&D and manufacturing. The highest-conviction bullish signal is Bavarian Nordic A/S's $1,264,240,981 award, representing 80% of total obligations and signaling strong demand in biotech preparedness. Albert B. Sabin Vaccine Institute, Inc. captured the remaining $310,144,424 across two neutral contracts for Sudan Ebolavirus and Marburg/Sudan vaccines, but its nonprofit status eliminates direct equity upside. Key watch item: option exercises on Sabin contracts toward $240M and $149.7M ceilings, with $62M and $88M already outlayed.

3 total filings
· daily

New Federal Contractors — May 13, 2026

This digest covers 6 new federal contractor awards totaling $4,176,750,195 in obligations, all civilian agency contracts (0/6 defense-related) from May 13, 2026. Dominant themes include massive construction and health-related commitments from DHS ($1.72B to Southwest Valley Constructors) and HHS ($1.26B to Bavarian Nordic A/S plus $310M across two to Albert B. Sabin Vaccine Institute), alongside VA IT services ($810M to Booz Allen Hamilton). Highest-conviction bullish signals stem from the top three high-materiality awards ($1.72B, $1.26B, $810M), signaling multi-year revenue stability for recipients despite limited defense exposure. Key risk is uneven outlay pacing, with Booz Allen at 39% ($318M of $810M), Sabin contracts at ~38-60%, and Nelson at 15% ($10.7M of $72.6M), warranting monitoring for funding continuity amid CR uncertainty.

6 total filings
· daily

Significant Contract Modifications ($10M+) — May 13, 2026

This digest synthesizes $4,176,750,195 in significant civilian contract modifications (0/6 defense-related) across DHS, HHS, VA, and USAID for the period May 13-13, 2026. Dominant agency themes include massive HHS commitments to vaccine developers ($1.26B to BAVARIAN NORDIC A/S and $310M across two awards to ALBERT B. SABIN VACCINE INSTITUTE, INC.) and large VA/DHS IT/construction plays ($810M Booz Allen Hamilton VA IT services; $1.72B Southwest Valley Constructors DHS). Highest-conviction bullish signal is Booz Allen Hamilton's $809.8M VA time-and-materials IT delivery order with $317.9M already outlayed and low pricing risk over 5+ years. Key risk/watch item: outlay pacing on long-term contracts (e.g., Sabin's HHS awards with $150.7M outlayed vs. $310M obligated; Nelson's $72.6M USAID with only $10.7M outlayed).

6 total filings
· daily

Contract Deobligations Alert — May 13, 2026

This Contract Deobligations Alert synthesizes $4,176,750,195 in total civilian contract obligations across 6 awards from May 13, 2026, with 0/6 defense-related and average signal strength of 5.5/10, dominated by DHS ($1.72B), HHS ($1.57B across Bavarian Nordic A/S and Albert B. Sabin Vaccine Institute), and VA ($810M). Highest-conviction bullish signals (7/10 strength, 8/10 materiality) highlight durable revenue potential for Southwest Valley Constructors Co ($1.72B DHS), Bavarian Nordic A/S ($1.26B HHS), and Booz Allen Hamilton Inc ($809.8M VA IT services). Neutral signals temper smaller HHS R&D awards to Albert B. Sabin Vaccine Institute ($310M total) and USAID remediation to Nelson Environmental Remediation USA Ltd ($72.6M). Key risk: monitor outlay progress on multi-year contracts like Booz Allen's remaining $492M unoutlayed on VA order and Nelson's high firm-fixed-price execution risk.

6 total filings
· daily

Contract Option Exercises — May 13, 2026

Option exercises totaling $4,176,750,195 across 6 civilian contracts (0/6 defense-related) highlight steady funding commitments from HHS ($1.57B in vaccine R&D), DHS ($1.72B construction), VA ($810M IT services), and USAID ($73M remediation), with average signal strength of 5.5/10. Dominant theme is civilian health preparedness via HHS awards to BAVARIAN NORDIC A/S ($1.26B) and ALBERT B. SABIN VACCINE INSTITUTE ($310M across two contracts), alongside large VA IT support for BOOZ ALLEN HAMILTON INC. Highest-conviction bullish signal is BOOZ ALLEN HAMILTON's $809.8M VA delivery order with $317.9M already outlayed under low-risk time-and-materials pricing through 2025. Key risk is uneven outlay pacing in multi-year contracts, such as BOOZ ALLEN's remaining $492M and NELSON ENVIRONMENTAL REMEDIATION USA LTD's early 15% ($10.7M) on $72.6M USAID award.

6 total filings
· daily

Federal IT & Cybersecurity Contracts — May 13, 2026

The single contract in this Federal IT & Cybersecurity stream represents a $809,754,946 obligation fully committed to Booz Allen Hamilton Inc. by the Department of Veterans Affairs, with 0% defense and 100% civilian exposure. This multi-year IT operations and services transformation delivery order underscores a stable, high-certainty revenue stream for Booz Allen Hamilton, evidenced by $317,898,571 already outlayed under a time and materials structure won via full and open competition. The highest-conviction bullish signal is the steady $140-145 million annual revenue estimate through 2025-01-22, highlighting VA's prioritization of integrated IT services (NAICS 541512, PSC D318). A key watch item is progress on the remaining ~$492 million in outlays and any modifications ahead of the 2025-01-22 end date, given uncertain outlay pacing.

1 total filings
· daily

All HHS Contracts — May 13, 2026

HHS obligated $1,574,385,405 across 3 contracts from May 13-13, 2026, with 0/3 defense-related (100% civilian HHS focus on BARDA/ASPR vaccine R&D for outbreak preparedness). The dominant theme is filovirus vaccine development (Sudan Ebolavirus, Marburg), led by highest-materiality $1.26B award to BAVARIAN NORDIC A/S (bullish signal, strength 7/10). Albert B. Sabin Vaccine Institute, Inc. (nonprofit) captured the remaining $310M in two neutral signals for similar R&D through 2030. Highest-conviction signal is bullish on BAVARIAN NORDIC A/S due to massive scale vs. Sabin's ~$20M annual revenue est. Key watch item: Sabin option exercises toward $240M and $149M ceilings amid $150M+ combined outlays to date.

3 total filings
· daily

Mega Contracts Monitor ($100M+) — May 13, 2026

These five civilian mega contracts totaling $4,104,180,352 (0/5 defense-related) highlight steady funding in health preparedness and IT services, with Department of Health and Human Services (HHS) dominating via BARDA vaccine R&D awards and Department of Homeland Security (DHS) leading with a $1.72B construction award to Southwest Valley Constructors Co. Highest-conviction bullish signals emerge from the top three contracts—Southwest Valley ($1.72B DHS), Bavarian Nordic A/S ($1.26B HHS), and Booz Allen Hamilton Inc. ($810M VA)—indicating multi-year revenue visibility amid low pricing risk. Two neutral signals to nonprofit Albert B. Sabin Vaccine Institute, Inc. ($310M combined HHS) underscore stable but non-equity-impacting R&D funding. Key watch item: outlay pacing on Booz Allen's $810M VA IT contract, where only $318M of $810M has been spent as performance nears 2025 end.

5 total filings
· daily

High-Value Federal Grants ($5M+) — May 13, 2026

This digest covers $4,176,750,195 in high-value federal grants ($5M+) awarded or obligated in the May 13, 2026 period, with 0/6 defense-related and all civilian agency focus across DHS, HHS, VA, and USAID. Dominant themes include large-scale construction (DHS to Southwest Valley Constructors Co $1.72B), biotech preparedness (HHS to Bavarian Nordic A/S $1.26B and Albert B. Sabin Vaccine Institute $310M combined), and IT services (VA to Booz Allen Hamilton Inc $810M). Highest-conviction bullish signals stem from the top three high-materiality awards ($3.79B total), signaling multi-year revenue stability for recipients amid full funding commitments. Key risk is uneven outlay pacing, with Booz Allen at $318M (39%) outlayed on its $810M award and Sabin contracts showing 38-60% progress, warranting monitoring for cash flow implications.

6 total filings
· daily

General Federal Contracts — May 13, 2026

This digest covers $4,176,750,195 in 6 civilian-only federal contracts (0/6 defense-related) awarded across DHS, HHS, VA, and USAID, dominated by three high-materiality bullish awards exceeding $800M each to Southwest Valley Constructors Co ($1.72B DHS), Bavarian Nordic A/S ($1.26B HHS), and Booz Allen Hamilton Inc ($810M VA). The highest-conviction signal is sustained civilian agency demand for construction, biotech, and IT services, with multi-year commitments providing revenue visibility through 2025-2030. Albert B. Sabin Vaccine Institute, Inc. captures two HHS awards totaling $310M for ebolavirus R&D and manufacturing, reinforcing HHS vaccine preparedness theme. Key risk is uneven outlay pacing, with Booz Allen at 39% ($318M of $810M), Sabin contracts at 38-60%, and Nelson at 15%. Average signal strength of 5.5/10 reflects neutral lower-tier awards amid stable civilian funding.

6 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 13, 2026

Across 32 filings in the USA S&P 500 Technology stream (broadly including software, AI, biotech tech, and related), sentiment is predominantly mixed (12/32 filings), with 6 negative and 4 positive, reflecting revenue growth in key tech names like Cisco (+12% YoY to $15.8B) and Formula Systems (+18% YoY to $2.6B) offset by declines in niche players like Planet 13 (-24.8% YoY) and CareView (-2% YoY). Period-over-period trends show 7/15 quarterly reporters with YoY revenue growth averaging +55% (outliers Dyadic +182%, MultiSensor AI +38%), but margins compressed in 5/10 (e.g., Cisco -200bps to 63.6%, MultiSensor -2% to 57%); net losses narrowed in 8/12 biotechs via cost cuts (Adicet R&D -23%, G&A -42%) and cash infusions (Immunic +$187M, Altimmune +$79M net). Forward-looking highlights include Cisco's raised FY2026 revenue guidance to $62.8-63.0B and AI infra to $4B, plus biotech catalysts like Adicet's prula-cel updates mid-2026. Capital allocation favors dividends (Cisco $0.42/share, Atmus $0.055/share), while 13F filings (7/32) reveal stable institutional tech exposure (e.g., Acadian's $3.89B Apple). Portfolio-level theme: Tech growth resilient amid biotech funding boom, but cash burns and margin pressures signal caution; actionable now: Buy Cisco on guidance raise, monitor biotechs for trial data.

11 high priority 21 medium 32 total filings